-
Breast cancers that are "triple-negative" (ie, ER, PR, HER2-negative) are considered high risk, yet there remains variability, with some demonstrating less malignant features than others.
-
Several important papers have been published in the last 2 months, none more important than the realization that breast cancer rates have dropped precipitously since the publication of the Women's Health Initiative (WHI) in 2002.
-
-
In 47 patients with newly diagnosed colorectal cancer, staging by combined CT and PET was compared to CT followed at a later time by PET or by CT alone.
-
Optimal treatment for carcinoma of unknown primary has not been established. In a multicenter, randomized Phase II trial, 66 patients were treated with cisplatin, gemcitabine and either paclitaxel or vinorelbine.
-
-
Immediate breast reconstruction after mastectomy has intuitive appeal, but concern has been raised that such an approach hinders postmastectomy radiotherapy.
-
Breast cancer patients who received either high-dose, standard-dose or no chemotherapy were studied prospectively, utilizing a comprehensive battery of neuropsych tests.
-
An increasing number of active therapies have become available for multiple myeloma in addition to high dose chemotherapy followed by autologous transplant (ASCT).
-
Patients with coronary artery disease who have received intra-coronary, drug-eluding stents (DES) may benefit from longer courses of clopidogrel than is currently standard.
